Maria Τektonidou: TMN Manifestation Scores and Mortality in Antiphospholipid Syndrome
Maria Τektonidou, Professor of Rheumatology at National and Kapodistrian University of Athens, shared a post on LinkedIn, about a recent article she and her colleagues co-authored, adding:
“Further Validation of the Eular Antiphospholipid syndrome disease activity score (Eapsdas). Criterion Validity using mortality as the criterion.
The maximum scores of thrombotic/microvascular/non-thrombotic (TMN) manifestations were significantly higher among patients who died due to Antiphospholipid Syndrome than among those who survived and those who died from other causes”
Title: Criterion validity of the EULAR Antiphospholipid Syndrome Disease Activity Score (EAPSDAS)
Authors: Maria G. Tektonidou, Ricard Cervera , Guillermo J. Pons-Estel , Savino Sciascia, Angela Tincani , Michael M. Ward
Read the Full Article on Annals of the Rheumatic Diseases
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 11, 2026, 15:24Calum Robb: A Simplified Flow Cytometry Method for Measuring Human NETs
-
Mar 11, 2026, 15:19Sharmila Manian: Why Color-Coding is a Lifesaver in Patient Blood Management
-
Mar 11, 2026, 15:10Carlos Andrés Vergara Sánchez: Insights From the POLY-ACS Trial on Post-ACS Medication Adherence
-
Mar 11, 2026, 15:03Abdul Mannan: Why Early Recognition of APML-Associated DIC Saves Lives
-
Mar 11, 2026, 15:02Archil Jaliashvili: World-First Use of HBOC-201 in a Double Organ Transplant Patient
-
Mar 11, 2026, 14:54Ludovic Helfgott: Grateful for Generosity in Supporting Patients with Hemophilia and Hemoglobinopathies
-
Mar 11, 2026, 14:26Cathy Harrison: Hemophilia Nurses Advocating for People Living With Bleeding Disorders
-
Mar 11, 2026, 13:47Carlos Andrés Vergara Sánchez: AI-Driven CCTA Plaque Quantification for Better ASCVD Risk Assessment
-
Mar 11, 2026, 13:44Scott Cameron: Metformin, Aspirin, and Sex-Specific Effects in Abdominal Aortic Aneurysm Growth